Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 12, 2012, Pages 1927-1936

  Förster, Stefan ^a,c   Yousefi, Behrooz H ^a   Wester, Hans Jürgen ^a   Klupp, Elisabeth ^a   Rominger, Axel ^b   Förstl, Hans ^a   Kurz, Alexander ^a   Grimmer, Timo ^a   Drzezga, Alexander ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alzheimer'sdisease; Amyloid deposition; Dementia; FDGPET; Hub region; Longitudinal study; Metabolism; PIB PET; Quantitative correlation; SUVR

Indexed keywords

AMYLOID; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HEMISPHERE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; QUANTITATIVE ANALYSIS;

AGED; ALZHEIMER DISEASE; AMYLOID; ANILINE COMPOUNDS; BRAIN; CASE-CONTROL STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 84869097232     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2230-9     Document Type: Article

References (40)

1. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
2. Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging 1997;18:S85-8. (Pubitemid 27454703)
3. Förster S, Buschert VC, Buchholz HG, Teipel SJ, Friese U, Zach C, et al. Effects of a 6-month cognitive intervention program on brain metabolism in amnestic mild cognitive impairment and mild Alzheimer's disease. J Alzheimers Dis 2011;25:695-706. doi:10.3233/JAD-2011-100996.
4. Förster S, Grimmer T, Miederer I, Henriksen G, Yousefi BH, Graner P, et al. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry 2012;71:792-7. doi:10.1016/j.biopsych.2011.04.023.
5. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002;159:738-45. (Pubitemid 34465046)
6. Förster S, Teipel S, Zach C, Rominger A, Cumming P, Fougere CL, et al. FDG-PET mapping the brain substrates of visuoconstructive processing in Alzheimer's disease. J Psychiatr Res 2010;44:462-9. doi:10.1016/j.jpsychires. 2009.09.012.
7. Förster S, Vaitl A, Teipel SJ, Yakushev I, Mustafa M, la Fougère C, et al. Functional representation of olfactory impairment in early Alzheimer's disease. J Alzheimers Dis 2010;22:581-91. doi:10.3233/JAD- 2010-091549.
8. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19. doi:10.1002/ana.20009. (Pubitemid 38269583)
9. Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009;72:1487-94. doi:10.1212/WNL. 0b013e3181a2e8d0.
10. Grimmer T, Riemenschneider M, Förstl H, Henriksen G, Klunk WE, Mathis CA, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009;65:927-34. doi:10.1016/j.biopsych.2009.01.027.
11. Jack Jr CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-65. doi:10.1093/brain/awp062.
12. Scheinin NM, Aalto S, Koikkalainen J, Lötjönen J, Karrasch M, Kemppainen N, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009;73:1186-92. doi:10.1212/WNL.0b013e3181bacf1b.
13. Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, Långström B, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 2012;33:198.e1-14. doi:10.1016/j. neurobiolaging.2010.06.015.
14. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2856-66. doi:10.1093/brain/awl178. (Pubitemid 44684508)
15. Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Aß and cognition in aging and Alzheimer disease. Ann Neurol 2011;69:181-92. doi:10.1002/ana.22248.
16. Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci 2009;29:14770-8. doi:10.1523/JNEURO-SCI.3669-09.2009.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44. (Pubitemid 14076461)
18. Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 2008;39:619-33. doi:10.1016/j.neuroimage.2007.09.020. (Pubitemid 350117638)
19. Ziolko SK, Weissfeld LA, Klunk WE, Mathis CA, Hoge JA, Lopresti BJ, et al. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage 2006;33:94-102. doi:10.1016/j.neuroimage.2006.05.063. (Pubitemid 44397577)
20. Hedden T, Van Dijk KR, Becker JA, Mehta A, Sperling RA, Johnson KA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci 2009;29:12686-94. doi:10.1523/JNEUROSCI. 3189-09.2009.
21. Drzezga A, Becker JA, Van Dijk KR, Sreenivasan A, Talukdar T, Sullivan C, et al. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 2011;134:1635-46. doi:10.1093/brain/awr066.
22. Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968-80. doi:10.1016/j.neuroimage.2006.01.021. (Pubitemid 44183792)
23. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-17. doi:10.1523/JNEUROSCI.2177-05.2005. (Pubitemid 41208641)
24. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 2008;1124:1-38. doi:10.1196/annals.1440.011. (Pubitemid 351506788)
25. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, et al. APP processing and synaptic function. Neuron 2003;37:925-37. (Pubitemid 36398299)
26. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005;48:913-22. doi:10.1016/j.neuron. 2005.10.028. (Pubitemid 41814696)
27. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A 2004;101:4637-42. doi:10.1073/pnas. 0308627101. (Pubitemid 38437463)
28. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011;32:1207-18. doi:10.1016/j.neurobiolaging.2009. 07.002.
29. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007;68:501-8. doi:10.1212/01.wnl.0000244749.20056.d4.
30. Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med 2007;48:547-52. (Pubitemid 47571408)
31. Grimmer T, Tholen S, Yousefi BH, Alexopoulos P, Förschler A, Förstl H, et al. Progression of cerebral amyloid load is associated with the apolipoprotein E e4 genotype in Alzheimer's disease. Biol Psychiatry 2010;68:879-84. doi:10.1016/j.biopsych.2010.05.013.
32. Tosun D, Schuff N, Mathis CA, Jagust W, Weiner MW, Alzheimer's Disease Neuroimaging Initiative. Spatial patterns of brain amyloidbeta burden and atrophy rate associations in mild cognitive impairment. Brain 2011;134:1077-88. doi:10.1093/brain/awr044.
33. Villain N, Fouquet M, Baron JC, Mézenge F, Landeau B, de La Sayette V, et al. Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain 2010;133:3301-14. doi:10.1093/brain/awq203.
34. Chételat G, Desgranges B, Landeau B, Mézenge F, Poline JB, de la Sayette V, et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 2008;131:60-71. doi:10.1093/brain/awm288.
35. Gouw AA, Seewann A, Vrenken H, van der Flier WM, Rozemuller JM, Barkhof F, et al. Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain 2008;131:3286-98. doi:10.1093/brain/awn265.
36. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 2008;1147:180-95. doi:10.1196/annals.1427.007.
37. Bai F, Zhang Z, Watson DR, Yu H, Shi Y, Yuan Y. Abnormal white matter independent of hippocampal atrophy in amnestic type mild cognitive impairment. Neurosci Lett 2009;462:147-51. doi:10.1016/j.neulet.2009.07.009.
38. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-91. doi:10.1126/science.1074069298/5594/789. (Pubitemid 35231524)
39. Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci 2010;13:190-6. doi:10.1038/nn. 2476.
40. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004;62:925-31. (Pubitemid 38435780)